Background-Ischemic mitral regurgitation (MR) is classically ascribed to functional restriction of normal leaflets, but recent studies have suggested post-myocardial infarction (MI) mitral valve (MV) leaflet fibrosis and thickening, challenging valve normality. Progression of leaflet thickness post-MI has not been studied. We hypothesized that excessive MV remodeling post-MI contributes to MR. Our objectives are to characterize MV changes after MI and relate them to MR. Methods and Results-Three groups of 40 patients with serial echocardiograms over a mean of 23.4 months were identified from an echocardiography database: patients first studied early (6±12 days) and late (12±7 years) after an inferior MI and normal controls. MV thickness was correlated with MR. We studied the mechanisms for MV changes in a sheep model (6 apical MI versus 6 controls) followed for 8 weeks, with MV cellular and histopathologic analyses. Early post-MI, leaflet thickness was found to be similar to controls (2.6±0.5 vs 2.5±0.4 mm; P=0.23) but significantly increased over time (2.5±0.4 to 2.9±0.4 mm; P<0.01). In this group, patients tolerating maximal doses of renin-angiotensin blocking agents had less thickening (25% of patients; P<0.01). The late-MI group had increased thickness (3.2±0.5 vs 2.5±0.4 mm; P<0.01) without progression. At follow-up, 48% of post-MI patients had more than mild MR. Increased thickness was independently associated with MR. Experimentally, 8 weeks post-MI, MVs were 2-fold thicker than controls, with increased collagen, profibrotic transforming growth factor-β, and endothelial-to-mesenchymal transformation, confirmed by flow cytometry. Conclusions-MV thickness increases post-MI and correlates with MR, suggesting an organic component to ischemic MR.
I schemic mitral regurgitation (MR) is a frequent
1 complication of myocardial infarction (MI), doubling heart failure and mortality. [2] [3] [4] Its primary mechanism is leaflet tethering by disturbed left ventricle (LV) geometry secondary to local or global remodeling. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Ischemic MR is considered functional, without contribution from intrinsic leaflet changes. The size of the valve was classically assumed to be fixed in the remodeling ventricle; however, the mitral valve (MV) can enlarge to adapt to ventricular expansion [17] [18] [19] [20] [21] and reduce MR. 18 Experimental studies have demonstrated that mechanical stretch induced by leaflet tethering can induce active valve growth. 19, 22 This compensatory mechanism, however, is frequently unable to compensate for LV distortion, and ischemic MR remains prevalent.
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Other work suggested that abnormal leaflets could contribute to functional MR: increased valve stiffness and collagen accumulation were observed in end-stage heart failure, suggesting organic MV alteration. 20, [23] [24] [25] Based on collagen synthesis upregulation in response to stress, 25 Kunzelman et al 26 showed by finite-element analysis that increased leaflet stiffness and thickness can interfere with MV function. Normal closure requires flexible leaflets to bend and form a coaptational seal, and normal MV can expand 15% in systole to close (Figure 1 ) 27, 28 ; these elements of normal function could be limited with stiffer leaflets. 26, 29 Mechanisms and clinical implications of these fibrotic changes have not been investigated. Especially, it is unclear if and how initially compensatory stretch-induced valve growth can progress toward maladaptive stiffening and thickening contributing to MR. In the setting of MI, numerous processes such as renin-angiotensin system activation are known to affect LV remodeling; but whether leaflet tissue can be involved in the remodeling process is unknown. [30] [31] [32] [33] We tested the hypothesis that post-MI MV changes could result in maladaptive fibrosis, with excessive thickening Mitral Valve Fibrosis After Myocardial Infarction contributing to MR. The prevalence and timing of valve thickening and their relation to MR were assessed. We studied over time 3 groups of patients: those with recent acute MI, those with remote MI, and normal controls. In a subsidiary study, we used a sheep model of MI to explore cellular and molecular mechanisms leading to fibrosis. To capture changes caused by MI without the papillary muscle displacement seen with inferoposterior MI or the associated MR, which can secondarily thicken the leaflets, 34, 35 we created limited antero-apical MIs that do not generate MR.
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Methods
Human Retrospective Follow-Up Study
We used our institution's echocardiography database to identify patients with documented MI involving at least the inferior or posterior walls, leaflet tethering, and at least 2 echocardiograms separated by ≥90 days (Figure 2) . 5 The first 40 consecutive patients were studied in each of the 3 groups: (1) patients with an echo within the first 3 weeks of a first MI and a follow-up study at least 90 days later (early-MI group); (2) patients with remote (>5 years) MI and comparable follow-up (late-MI group); and (3) control subjects (comparable age and sex to both MI groups) with similar follow-up to control for changes in leaflet thickness with aging. 36 The control group consisted of patients with serial normal echoes either after foramen ovale closure or screening for chemotherapy-induced cardiomyopathy. Exclusion criteria were more than mild aortic stenosis or insufficiency, MV organic pathology (prolapse, rheumatic, endocarditis, or extensive annular calcification), valve prosthesis, Marfan disease, and patient taking anti-parkinsonian dopamine agonists.
Echocardiographic Analysis
All echocardiograms were reviewed blinded to the patient group and timing of the examination (Figure 3 ). MV thickness was measured in parasternal long-axis and apical zoomed views in a diastolic frame without valve motion, with leaflets perpendicular to the echocardiographic beam, taking advantage of the axial resolution. This was achieved at mid-diastole in parasternal view and end-diastole in apical views. Thickness was measured 3× for both leaflets in both views in areas free of chordal attachment; all values were averaged. [37] [38] [39] A subset of 10 patients was measured by 2 investigators and 1 month later by the first investigator for interobserver and intraobserver variabilities. MV excursion angle between end-systole and full opening was measured in the parasternal long-axis view. 40 LV end-diastolic and end-systolic dimensions were measured and LV ejection fraction (EF) calculated (modified Quinones method). MR was graded independently by 2 level-3 readers (discrepancies were resolved by a third reader as needed) as suggested by current guidelines with an integrated approach using all available parameters. 41 or regurgitant volume >30 mL) has been shown to have a prognostic impact. 3 For that reason, greater than mild MR was considered significant in our study. Progression of MR was defined as an increase of at least one grade of MR between baseline and follow-up studies. Medical records were reviewed for clinical characteristics and medication profile. The study was approved by the institutional review committee.
Experimental Study
Six adult Dorsett hybrid sheep underwent left anterior descending artery ligation, and 6 had sham thoracotomy. Epicardial echocardiography was done at baseline and euthanasia. MVs were harvested at 8 weeks for analyses. Thickness (averaged over 10 thickest midleaflet sites), valve morphology, and collagen accumulation were analyzed by Hematoxylin/Eosin and Masson's trichrome staining. Cellular activation (endothelial-to-mesenchymal transformation [EMT]) was assessed by staining for endothelial (CD31) and interstitial myofibroblast (α-smooth muscle actin [α-SMA]) markers. EMT was confirmed by flow cytometry of dissociated fresh valve endothelial cells with fluorescent anti-CD31 and anti-α-SMA labeling. Transforming growth factor (TGF-β) was assessed by immunohistochemistry as an initial measure of growth signaling promoting both EMT and fibrosis.
Statistics
Continuous variable were expressed as mean±standard deviation, and categorical variables as number (%). Differences in means were tested for significance with Student's t tests and differences in proportions with χ 2 tests. Differences in thickness over time among groups were assessed with repeated-measures analysis of variance and paired t test. Variables associated with more than mild MR for all post-MI patients at follow-up were assessed by logistic regression. Leaflet thickness, LVEF, LV end-diastolic dimension, LV endsystolic dimension, age, leaflet excursion, time from infarct date, tethering distances (from papillary muscles to annulus), left atrial dimension, and annulus dimensions (apical 2-and 4-chamber views) in midsystole 14 were tested in univariate analysis, and variables with P<0.05 were tested in multivariable model. Interobserver and intraobserver agreements of leaflet thickness measurements were assessed using a single measure, 2-way random effect intraclass correlation coefficient. Values of 0.893 (interobserver) and 0.946 (intraobserver) were obtained. Correlation and Bland-Altman plots are presented in Figure I in the Data Supplement. In the animal model, EMT by flow cytometry and echocardiographic measures were compared between MI and control groups with t tests. Statistical analysis was performed with Stata/IC 11.2 (StataCorp LP, TX).
Results
Human Studies
A total of 120 patients were studied, each with 2 echocardiographic studies. The first echocardiogram was performed 6±12 days post-MI (85% within 1 week) in the early-MI group and 12±7 years post-MI in the late-MI group. There was no significant difference in age, sex, or median follow-up time (642, 544, and 773 days) among groups. Both MI groups had lower LVEF and larger LV dimensions than normal group (Table 1) . Most patients had revascularization at the time of MI (early-MI, 33/40; late-MI, 36/40). Primary PCI was the preferred revascularization strategy for both groups (70% and 60% for early-MI and late-MI groups). Reasons for nonrevascularization included late presentation without ongoing chest pain, absence of reversible ischemia on noninvasive testing, or patients refusing invasive procedures.
Mitral Valve Thickness and Motion
Average MV thickness was stable over time in the control group (2.6±0.5 to 2.6±0.5 mm; P=0.71; Figure 4 ). The early-MI group had initially similar thickness to controls (2.5±0.4 versus 2.6±0.5 mm; P=0.23) but showed significant progression over time (2.5±0.4 to 2.9±0.4 mm; P<0.001). The proportion of early-MI patients with thickness >3 mm increased from 13% at baseline to 43% at follow-up (P<0.01; see example in Figure 3 and Movie I through III in the Data Supplement). Late-MI patients had thicker leaflets compared with early-MI and control patients at baseline (3.2±0.5 versus 2.5±0.4 versus 2.6±0.5 mm for late-MI, early-MI, and controls; P<0.01). The proportion of patients with increased thickness was higher in the late-MI group (68%, 13%, and 18% of patients had thickness >3 mm in late-MI, early-MI, and control groups; P<0.01). Despite increased thickness at baseline, the late-MI group had no progression over time. Opening excursion for both leaflets was stable over time in the control group. At baseline, the early-MI group had decreased excursion compared with controls, and there was an additional significant decrease at follow-up (Table 2 and Figure 3 ). The late-MI group had reduced leaflet excursion at baseline compared with control and early-MI groups but was stable over time. There was no significant difference in leaflet thickness for patients with versus without revascularization or post-MI ischemia by noninvasive tests (P=NS for all). There was no observed difference in thickness for patients with associated comorbidities (diabetes mellitus, renal failure, hypertension, hyperlipemia, or active smoking). No difference in thickness was observed based on the echocardiography system used (51% Philips ie-33; 31% Philips Sonos 7500; 18% GE Vivid 7).
Effect of Medication on Thickness
Medication profile is shown in Table 1 : 75% of late-MI and 93% of early-MI patients were treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers ( Figure 5 ). However, the tolerated dose was low (<50% of maximal dose for a given medication) for a significant proportion of patients (66/80). In an exploratory analysis, we tested the hypothesis that leaflet thickness progression could be different in patients taking higher doses of angiotensinconverting enzyme inhibitor or angiotensin receptor blockers. In the subgroup of early-MI patients taking higher doses, there was no significant leaflet thickening (high doses: 2.6±0.4 to 2.7±0.6 mm, P=0.44; low doses: 2.5±0.4 to 2.9±0.4 mm, P<0.01). In the late-MI group, anterior leaflets were thinner in the high-dose subgroup (anterior thickness: 2.9±0.6 versus 3.4±0.5 mm; P=0.04) However, our study was not designed and had limited power to assess this difference.
Association of Leaflet Thickness and Ischemic MR
In the pooled ensemble of post-MI patients, those with increase of at least 1 grade of MR at follow-up versus baseline had also significant increase in average leaflet thickness (+0.43±0.46 versus +0.06±0.46 mm, for patients with versus without MR progression; P=0.002; Figure 5 ). At follow-up, there was a significant association between leaflet thickness and greater than mild MR (average thickness 3.2±0.5 versus 2.8±0.4, P=0.0006, 
Experimental Mechanistic Study
All animals survived until euthanasia; none developed MR. There was a mild decrease in LVEF post-MI (61±7% to 47±4%; P<0.01). MV thickness (microscopy) was significantly increased post-MI versus sham (1.02±0.23 versus 0.44±0.11 mm; P<0.01). Histopathology post-MI showed expansion of the central spongiosa layer and focal subendothelial deposition of collagen, primarily on the atrial leaflet surface (Figure 6, arrows) .
Cellular Changes
The endothelial layer of control MVs had CD31 + cells without α-SMA staining (Figure 7) . In contrast, post-MI MVs were positive for both CD31 and α-SMA, indicating EMT. By flow cytometry, endothelial cells coexpressing α-SMA were more common in post-MI versus sham MVs (48±14% versus 7±4% of endothelial cells; P<0.01). The endothelium and subendothelial interstitium were strongly positive for TGF-β1, colocalized to regions of α-SMA staining.
Discussion
In this study, we demonstrate that MV presents echocardiographic changes post-MI: (1) Early post-MI, leaflet thickness is initially normal but increases over time; (2) Late post-MI, thickness is 36 lack of increase in a control group of comparable age, sex, and follow-up time indicates that this is not a likely explanation for the changes observed early post-MI.
The capacity for MV remodeling in functional MR has been demonstrated previously. [17] [18] [19] 23, 24, 26, 27, 35 While active valve expansion can be seen as adaptive, excessive remodeling can lead to fibrosis with increased thickness, decreased mobility, and potentially more MR because effective closure requires systolic expansion and flexibility. 26 Although differences between the late-MI and control groups could be related to other comorbidities, the evolution of changes in the early-MI cohort and the large-animal study are consistent, with changes beginning only after MI, mainly in the early period, as the late-MI group showed stable thickness.
Mechanistic Considerations
Ischemic MR is the complex result of mechanical stretch in an ischemic environment with subsequent heart failure-related humoral activation. A previous study from our group demonstrated that mechanical stretch alone from papillary muscle displacement causes active valve enlargement. 19 In the experimental portion of the current study, we show that an apical MI without papillary muscle involvement also triggers MV alterations. Importantly, strong TGF-β staining post-MI was not observed in the stretch-only model, suggesting a specific role for the ischemic environment on MV remodeling. While MR itself could contribute to the observed changes through increased turbulence and shear stress, 34, 35 the animal cohort showed a cluster of histological changes in the absence of MR.
Activation of renin-angiotensin system is well known post-MI, 43 and angiotensin II can trigger TGF-β expression in the heart, [44] [45] [46] with subsequent collagen deposition and extracellular matrix remodeling. Our observations suggest that valve leaflets can be involved in the global post-MI remodeling, and increased TGF-β likely plays a role in the observed leaflet changes (Figure 8 ). Although our clinical study was not primarily designed to assess the effect of medication on MV thickness, the observed relation between angiotensin-converting enzyme inhibitor/angiotensin receptor blockers doses and leaflet thickness post-MI deserves attention because it is consistent with TGF-β involvement: renin-angiotensin system blockade is known to inhibit profibrotic effects of TGF-β in various organs, 47, 48 including blood vessels and myocardium. 49, 50 Our data suggest a possible effect of TGF-β on MV remodeling, which could represent a pharmacological target. Although we cannot directly link MR to these histological changes in this experimental work, these observations warrant further investigations because this could be a first step toward medical approaches targeting leaflet fibrosis to prevent ischemic MR.
Clinical Significance of Increased Leaflet Thickness
This study challenges the concept that ischemic MR is exclusively related to LV remodeling. It is reasonable to suggest that disturbed extracellular matrix can change the mechanical properties of the valve, increasing its stiffness. 23, 26 This can limit MV closure by decreasing systolic expansion, limiting flexible leaflet bending, and potentially decreasing adaptive valve growth as compensatory enlargement is attenuated in these patients. 18, 21 All MI patients had the substrates for 
Limitations
The human data are retrospective, and unknown factors not accounted for could have explained differences in thickness between groups, but not likely within the early-MI group over time. MR quantification can change according to loading conditions. Our population was limited to preselected patients (inferior MI and leaflet tethering) more likely to have ischemic MR. Difference in individual follow-up timing, absence of 3D valve metrics and relatively small sample size are other limitations. Noninvasive ways to measure fibrosis and biomechanical properties of cardiac valves are limited, but a finite-element model previously demonstrated that increased thickness can impair coaptation. 26 Although leaflet thickness was assessed noninvasively in the clinical study, our protocol (averaging 12 measures/patient) showed good reproducibility and correlated well with previous studies 36 ; leaflet thickening post-MI was confirmed by pathology in the sheep study. Despite small sample size in the animal study, observed differences were consistent and highly significant. Our animal protocol included apical MI without MR (contrasting with the clinical study: inferior MI with high ischemic MR prevalence); this was important to demonstrate that the observed leaflet changes are not limited to inferior MI or MR itself. Interestingly, decreased diastolic excursion paralleled the increase in thickness post-MI. Although this can be attributed to decreased cardiac output or diastolic tethering, 40 intrinsic leaflet changes could also explain this phenomenon in part and could be explored in future biomechanical studies.
Conclusion
MV undergo multiple changes post-MI. Excessive valve remodeling can result in maladaptive fibrosis, suggesting an organic component in ischemic MR. The role of TGF-β and renin-angiotensin system to modulate this remodeling merits exploration.
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